Goodwin advised Mariana Oncology on the fundraising. Mariana Oncology Inc. announced its oversubscribed $175 million Series B financing co-led by Deep Track Capital and Forbion, and...
You must be a Standard 1 Year member to access this content.
Goodwin advised K36 Therapeutics on the financing. K36 Therapeutics announced a $70M Series B financing. The round was led by Nextech Invest, Ltd, a precision medicine focused...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised SonoThera, Inc. on the deal. SonoThera, Inc. announced its $60.75 million Series A financing round to support the continued development of SonoThera’s ultrasound-guided, nonviral,...
You must be a Standard 1 Year member to access this content.
Goodwin advised Nuvig Therapeutics on the deal. Nuvig Therapeutics announced its $47 million Series A financing and the launch of the company to develop novel therapeutics that...
You must be a Standard 1 Year member to access this content.
Goodwin advised LifeMine Therapeutics on the deal. LifeMine Therapeutics announced its completion of a $175 million Series C financing. LifeMine Therapeutics is reinventing drug discovery by mining...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Vida Ventures on the deal while Goodwin Procter represented Vigil Neuroscience. Vigil Neuroscience, a biotechnology company harnessing the power of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Prime Medicine™ on the deal. Prime Medicine™ announced its launch and funding rounds totaling $315 million. Prime Medicine is a biotechnology company founded to...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised AbSci on the deal. AbSci, a pioneering synthetic biology company that unifies biologic drug discovery and development processes, announced a $125 million crossover financing. The...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Monte Rosa Therapeutics on the deal. Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing...
You must be a Standard 1 Year member to access this content.
